IKZF1 and acute lymphoblastic leukemia: Song et al. [43] demonstrated the antileukemic effects of CK2 inhibitors in patient derived xenograft models of Ph-like ALL where CK2 inhibition increased the activity of IKAROS protein produced in cells with monoallelic IKZF1 deletion.